Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
4.19
Nov 16 • 3:59 PM ET Dollar change-0.17 Percentage change(-3.90%)
Aftermarket Close
4.14
Aftermarket • 5:00 PM ET Dollar change-0.05 Percentage change(-1.18%)
Index
-
Market Cap
290.21M
Enterprise Value
201.01M
Income
-73.31M
Sales
0.00M
Book/sh
1.49
Cash/sh
1.51
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
56
IPO
May 06, 2022
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
2.82
P/C
2.77
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
8.70
Current Ratio
8.70
Debt/Eq
0.15
LT Debt/Eq
0.12
Option/Short
Yes / Yes
EPS (ttm)
-1.06
EPS next Y
-1.05
EPS next Q
-0.31
EPS this Y
49.12%
EPS next Y
2.38%
EPS next 5Y
20.80%
EPS past 3/5Y
10.01% -63.43%
Sales past 3/5Y
- -
EPS Y/Y TTM
62.59%
Sales Y/Y TTM
-
EPS Q/Q
46.63%
Sales Q/Q
-
Insider Own
10.77%
Insider Trans
-0.02%
Inst Own
75.20%
Inst Trans
-4.06%
ROA
-46.13%
ROE
-55.07%
ROIC
-63.51%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
37.15%
SMA50
48.69%
SMA200
43.09%
Trades
Shs Outstand
69.26M
Shs Float
61.80M
52W High
7.80 -46.28%
52W Low
1.31 219.85%
Volatility
19.92% 11.78%
ATR (14)
0.54
RSI (14)
63.33
Beta
1.90
Rel Volume
0.87
Avg Volume
2.98M
Volume
2,606,679
Perf Week
75.31%
Perf Month
61.15%
Perf Quarter
43.99%
Perf Half Y
185.03%
Perf YTD
-35.64%
Perf Year
-11.60%
Perf 3Y
0.72%
Perf 5Y
-
Perf 10Y
-
Prev Close
4.36
Price
4.19
Change %
-3.90%
Consensus
Strong Buy
Avg. Price Target
$14.00
Implied Upside
+234.1%
Analysts4incl. previous ratings
Rating Distribution3 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 10, 2026Upgrade
BAC logoBBofA Securities
Underperform → Neutral$2.50 → $6+43.2%
Jun 16, 2026Initiated
CCraig Hallum
Buy$11+162.5%
Sep 09, 2025Initiated
GGuggenheim
Buy$6+43.2%
Dec 16, 2024Downgrade
BAC logoBBofA Securities
Neutral → Underperform$3-28.4%
Jul 31, 2024Downgrade
BAC logoBBofA Securities
Buy → Neutral$12+186.4%
Dec 21, 2022Initiated
HH.C. Wainwright
Buy$26+520.5%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kasraian KasraChief Technical OfficerMay 21 '26Sale1.411,2331,73950,074May 26 04:43 PM
STRECK PAULEVP, Head of R&DMar 04 '26Sale6.231,87911,70976,226Mar 06 04:14 PM
Donnelly NoelChief Financial OfficerMar 04 '26Sale6.232,08412,988111,603Mar 06 04:12 PM
McArthur James GPresident and CEOMar 04 '26Sale6.235,27532,876296,326Mar 06 04:09 PM
PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded on November 9, 2020 and is headquartered in Boston, MA.
PresidentDr. James G. McArthur Ph.D.
Chief Financial OfficerMr. Noel P. Donnelly M.B.A.
J.D.Mr. Joseph D. Vittiglio Esq.
Chief Technical OfficerDr. Kasra Kasraian Ph.D.
Senior Vice President of HR & AdministrationMs. Emiko Bryant